2019年 · 第58卷第09期

February 11, 2019JAMA NeurologyA study "Effect of ABCB1 gene polymorphism on the efficacy of clopidogrel in the treatment of acute ischemic stroke/transient ischemic attack" led by Professor Wang Yongjun, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University was published online [Pan Y, Chen W, Wang Y, et al. Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial. JAMA Neurol, 2019, 76 (5): 552 – 560.]. This study is based on the results of the gene subgroup study of Professor Wang Yongjun's team "clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE)". On the basis of this, the effect of ABCB1 gene polymorphism on the efficacy of clopidogrel was further detected and analyzed. The study found that the efficacy of clopidogrel treatment decreased in patients with acute mild ischemic stroke/transient ischemic attack (TIA) carrying the ABCB1-154 TC/CC or 3435 CT/TT genotype. The results of this study are another breakthrough in precision medicine research of cerebrovascular diseases, and have important reference value for the rational use of antiplatelet drugs in stroke patients in China in the future.